Robigo Secures Series A Funding Led by Leaps by Bayer

Robigo Secures Series A Funding

Robigo, a biotechnology company based in Cambridge, Massachusetts, has raised an undisclosed amount in a Series A funding round. The round was led by Leaps by Bayer, with participation from other notable investors including Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. Robigo specializes in programming biology to improve food production, aiming to revolutionize the way food is grown.

Leadership and Vision

The company is led by Andee Wallace, who serves as both the CEO and Founder. Wallace, who holds a PhD, is focused on leveraging biological programming to address challenges in agriculture and enhance the quality and sustainability of food production.

Key Investors

The Series A round was spearheaded by Leaps by Bayer, a venture capital arm known for investing in transformative health and agriculture solutions. Additional support came from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8, indicating a strong backing from investors interested in innovative biotech solutions.

Use of Funds

While specific details on the use of the new capital were not disclosed, it is expected that the funds will be utilized to further develop Robigo’s technology platform, expand its team, and accelerate product development to enhance its impact on the agricultural sector.

This funding round marks a significant milestone for Robigo as it continues to advance its mission of transforming food production through cutting-edge biotechnology.